|
|
|
Summary
of 2000 CPCRA Posters and Presentations
| 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 18, 2000, Toronto, Canada |
Abrams DI, Bebchuk JD, Denning ET, Markowitz NP. IL-2 therapy produces no change in HIV RNA after one year. Oral.
| XIII International AIDS Conference, July 10, 2000, Durban, South Africa |
Shade SB, Rappoport C, LeSueru D, Mullin C, Eberly L. Gender differences in viral load: Results from six clinical trials. Poster.
Raghavan S, Chen L, El-Sadr W, Grunfeld C, Peng G, Yurik T, MacArthur R. Prevalence and factors associated with fasting hypercholesterolemia, hypertriglyceridemia, and hyperglycemia in ethnically diverse antiretroviral naïve patients (CPCRA 058). Poster.
Andrews L, Friedland G, Mannheimer S, Morse E, Miller C, Brizz B, Matts J, Child C, Reilly N, Clax P, Choudhry N. A method for assessing patient readiness to begin and adhere to highly active antiretroviral therpay (HAART). Poster.
El-Sadr W, Bebchuk J. The effect of gender on progression of HIV disease among patients on combination antiretroviral therapy. Oral.
Mannheimer S. Matts J, Chen L, Child C, MacArthur R, Kostman J, et al. Self-reported antiretroviral adherence levels correlate with HIV viral load and decline over time. Oral.
| XX International Biometric Conference, July 2-7, 2000, Berkeley, CA |
Eberly L, Liu J. Relation of coenrollment to AIDS clinical trials outcomes. Oral.
| 2nd Symposium on HIV Drug Resistance, February 26, 2000, Frankfurt, Germany |
Kolberg J, Thompson M, Baxter J, Dehlinger M, Howard S, Zamroud M, Mayers D, Neaton J. Low levels of pre-existing mutant virus blunts HIV-1 response to therapy. Oral and poster.
| 7th Conference on Retroviruses and Opportunistic Infections, January 30, 2000, San Francisco, CA |
El-Sadr WM, Collins G, Raghavan S, Rappoport C, Gibert C, Carr A, Bartsch G. Prevalence of metabolic complications in a large diverse cohort of HIV-infected persons. Poster.
Burman W, El-Sadr W, Grant L, Matts J, Zeh D, Gallagher B, Hafner R, Crane L, Gordin F. Low rates of all Opportunistic infections among patients with advanced HIV disease responding to antiretrovral therapy - the CPCRA 048 cohort. Poster.
El-Sadr WM, Burman W, Grant L, Matts JP, Zeh D, Crane L, Gallagher B, Gordin F, Hafner R.
Prophylaxis (PROPHY) for Mycobacterium avium complex (MAC) can be deferred among patients
(pts) with a past CD4 count <50 cells/mm3 who responded to antiretroviral therapy (ART): Results of
a placebo (PLC)-controlled trial (CPCRA 048). Poster.
|
|
